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ABSTRACT
Metabolomics is complementary to genomics, transcriptomics and proteomics;
however, it has the capacity to reflect the activities of the organism at a functional
level. Metabolomics can therefore be used as a diagnostic tool by identifying the up- or
down-regulation of metabolites in the cell, tissue, plasma, serum or urine. Specifically,
these are, but are not limited to, identifying biomarkers of disease, monitoring drug
treatments, and monitoring surgical procedures such as organ transplant. Autosomal
recessive polycystic kidney disease (ARPKD) makes up 5-8% of patients requiring
kidney dialysis and/or transplantation and of these, an estimated 50% of patients
progress to end-stage renal disease (ESRD) by the age of 10 years, resulting in renal
and liver-related morbidity and mortality. The purpose of this research was to utilise
the Lewis Polycystic Kidney (LPK) rat to investigate the ARPKD phenotype using
metabolomics. Spot urine samples were collected from 7 male Lewis; 8 male LPK; and

6 female LPK rats aged 5 weeks. Metabolites were extracted from urine and
derivatised for GC/MS analysis. The peak area of target components was normalised to
the internal standard ribitol and then to creatinine. Principal component analysis (PCA)
was used to visualise sample grouping and the loadings plot of the PCA was used to
determine key metabolites attributed to the variance between sample groups. aketoglutarate, uric acid and allantoin were proposed as potential biomarkers for
ARPKD in the 5-week old male LPK rat. The findings of this study, particularly the
development of a GC/MS method to analyse Lewis and LPK rat urine, demonstrate the
potential of metabolomics to further investigate ARPKD.
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CHAPTER ONE
INTRODUCTION

1.1

Metabolomics
The relatively new field of metabolomics is defined as the study of the

metabolome (i.e. all metabolites in the cell, tissue and/or biofluid(s)) [1-5].
Metabolomics is complementary to genomics, transcriptomics and proteomics,
however, it has the capacity to reflect the activities of the organism at a functional
level [6, 7]. Metabolites are products of enzyme-catalysed reactions [8] and, although
it is known that changes in the quantities of enzymes may have little effect on
metabolic processes, significant effects can be seen in the concentration of individual
metabolites [6]. As this suggests, metabolites are integral to the function and survival
of the cell [3], most commonly participating in the production and release of energy or
as a precursor to such transfer processes [3]. Metabolomics can therefore be used as a
diagnostic tool by identifying the up- or down-regulation of metabolites in the cell,
tissue, plasma, serum or urine [9]. Specifically, these are, but are not limited to,
identifying biomarkers of disease [9], monitoring drug treatments [9, 10] and
monitoring surgical procedures such as organ transplant [4, 5].

Also termed metabonomics or metabolic profiling [4], the advent of
metabolomics has been in light of recent technological advancements in the
separation and identification of small, low molecular weight molecules [4, 11], and also
in software for processing the resultant large quantities of data [5]. As the properties
of metabolites such as polarity, volatility and solubility vary so greatly, metabolomic
analysis requires the use of several complimentary analytical techniques [2]. The most
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common approaches in metabolomics have been capillary electrophoresis [12, 13], gas
chromatography mass spectrometry {GC/MS) [2, 8, 14, 15], liquid chromatography
mass spectrometry {LC/MS) [2, 14, 16] and proton nuclear magnetic resonance
1

spectroscopy { H NMR) [1, 14, 16]. GC/MS is the method of choice for the screening of
non-targeted metabolites due to its ability to resolve hundreds of metabolites in a
single injection [2]. Coupled with the sensitivity and ability of MS to provide structural
information, the detection, separation and identification of metabolites is now
possible [2].

Gas chromatography has been widely used in metabolomics studies [3, 6, 8-10,
15, 17-20]. GC consists of an injection system, mobile phase, the column (stationary
phase) and a detector [3, 21]. A sample (gas or liquid) is injected through a septum into
an injection port and is rapidly volatilised [21]. Analytes are swept onto the column
and are separated according to volatility and diffusion between the mobile and
stationary phases [21]. Separated analytes then flow through to the detector which
records a response [21].

The mobile phase in gas chromatography is known as the carrier gas, and is
typically helium, nitrogen, or hydrogen [21]. The carrier gas used is largely dependent
upon the detector employed however, where the detector is not an issue, significant
differences can be found in separation efficiency and the speed of GC analysis by
selecting the appropriate carrier gas [21]. For example, hydrogen will yield the fastest
separation time followed by helium and then nitrogen [21]. In metabolomics, however,
mass spectrometers are generally used as the method of detection in gas
chromatography [3]. For this reason, helium is employed as the carrier gas. Helium and
2

hydrogen show superior resolution as analytes diffuse between phases more rapidly
through these carrier gases than through nitrogen [21]. Hydrogen may protonate
analytes and can potentially interfere with the MS vacuum pump [21]. For these
reasons, helium is the obvious choice of carrier gas in metabolomics separations using
GC/MS.

The method of injection in gas chromatography is critical as it is at this point
that the sample is transferred to the mobile phase and focused at the beginning of the
column [3]. Villas-Boas eta/. [3] have identified this as one of the major causes of error
in gas chromatography, being particularly attributed to slow and/or incomplete
volatilisation of analytes. To prevent this, metabolites must be converted to a volatile
form. This process is known as derivatisation and is a considerable limitation of GC/MS
due to its arduous and time consuming nature. Splitless injections are widely used in
non-targeted metabolic profiling [9, 15, 17, 19] as these are typically classed as trace
analyses. A split injection is commonly used to achieve baseline separation when the
concentration of a sample is known to be high or is unknown. It is a preventative
measure to minimise overloading the column and this is especially the case when using
capillary columns as micrograms of analyte can cause overloading [21].

There is a wealth of column technology available to GC practitioners.
Essentially, there are two types of GC columns; packed and open. Open tubular
columns are the most commonly used in GC analyses. They are long and narrow in
structure and are made of polyimide-coated fused silica. Open tubular columns offer
greater sensitivity, higher resolution, and shorter analysis time [21]. These features
make the application of open tubular columns ideal for research in the field of

3

metabolomics. The common coupling of GC to MS requires Low bleed columns. These
are typically non-polar capillary columns which amplify the need for derivatisation (i.e.
to reduce the polarity of metabolites) for successful high resolution chromatography.

Mass spectrometry is commonly employed as the method of detection in
metabolomics research [7, 11, 22]. In fact, Villas-Boas eta/. [3] have identified mass
spectrometry as the driving force behind the recent emergence of metabolomics. To
briefly describe MS, molecules are ionised by either electron or chemical ionisation
processes, are accelerated by an electric field and then separated according to their
mass-to-charge (m/z) ratio [21]. There are many different types of mass spectrometers
however, for the purpose of this research, only two will be discussed here. These are
the linear quadrupole mass spectrometer and the ion trap quadrupole mass
spectrometer.

In linear quadrupole mass spectrometry, four rods are assembled parallel to
one another. A constant voltage and a radio frequency oscillating voltage are applied
to the rods to stabilise the ion trajectory for a given

m/z species as it migrates to the

detector. This can, however, result in the loss of sensitivity for destabilised ions. In ion
trap quadrupole mass spectrometry, ions are trapped by a ring electrode and two end
caps. ion trajectories are destabilised in order to reach the detector in a uniform
stream which results in superior sensitivity in comparison to the linear quadrupole
mass spectrometer.

4

1.2

Polycystic Kidney Disease
Polycystic kidney .diseases (PKD) are inherited diseases characterised by renal

tubular defects [23]. Advances in molecular genetics have allowed the characterisation
of the three PKD genes; PKD1, PKD2 and PKHD1 [24]. By combining these findings with
the descriptive data obtained from previous mapping of genetic cystic diseases, the
molecular and cellular mechanisms of the diseases can now be systematically and
thoroughly investigated [24]. Two modes of inheritance have been characterised for
the polycystic kidney diseases. The first and most common is autosomal dominant
polycystic kidney disease (ADPKD) which is caused by mutations in the PKD1 (polycystic
kidney disease 1) or PKD2 (polycystic kidney disease 2) genes [25] and results in focal
cyst development [23]. The second is autosomal recessive polycystic kidney disease
(ARPKD) which is caused by mutations in the PKHD1 (polycystic kidney and hepatic
disease 1) gene [25], commonly resulting in tubule dilation [23, 26, 27].

Autosomal recessive polycystic kidney disease (ARPKD), far less common than
ADPKD, has an incidence of 1 in 20 000 [24, 28] which makes up 5-8% of patients
requiring kidney dialysis and/or transplantation [24]. Unlike ADPKD, ARPKD is most
commonly evident in utero or at birth but has also been characterised in later
childhood and in patients over 20 years of age [24, 28]. An estimated 50% of patients
progress to end-stage renal disease (ESRD) by the age of 10 years, resulting in renal
and liver-related morbidity and mortality despite recent advancements in neonatal
and intensive care [24].

5

Symptoms of ARPKD include fusiform dilation of renal collecting tubules or
ducts and/or focal cyst development [23] as well as dysgenesis of the hepatic portal
triad (congenital hepatic fibrosis) [24]. As this suggests, ARPKD is a member of a group
of congenital hepatorenal fibrocystic diseases [29] characterised by both renal and
hepatic involvement [24]. Dilation of the collecting tubules can be evident in 10-90% of
tubules, accounting for the vast variability in renal dysfunction and kidney
enlargement [24]. The manifestation of liver disease consisting of biliary dysgenesis
and congenital hepatic fibrosis varies from patient to patient according to age at
presentation, however liver involvement is a symptom of all ARPKD patients [24]. The
most common cause of morbidity and mortality in new born patients is pulmonary
hypoplasia, often resulting in respiratory insufficiency [24]. However, for patients who
survive the neonatal and perinatal periods, ARPKD can present with systemic
hypertension, renal failure, portal hypertension, and fibrosis of both the kidneys and
liver also resulting in morbidity and mortality [24].

The different phenotypes of the disease were originally thought to be caused
by different mutant genes [24]. Since then, all phenotypes of ARPKD have been
attributed to a mutation at a single locus; the PKHD1 (polycystic kidney and hepatic
disease 1) gene, which is located on chromosome 6p21.1-p12 [24, 30]. PKHD1 is a
large gene, spanning approximately 470 kb of genomic DNA and producing eDNA of 916 kb [24, 28]. A minimum of 86 exons is assembled into a variety of alternatively
spliced transcripts [24, 28]. The longest continuous open reading frame {ORF) is
predicted to yield a 4074-amino acid protein called fibrocystin or polyductin which is
believed to be involved in collecting tubule and biliary duct formation, however the
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exact function is unknown [24, 31]. It is anticipated that multiple variations of the
protein are produced by the complicated transcription of the PKHD1 gene [24].

Recent research in ARPKD has centred on determining the localisation and
function of the PKHD1 protein fibrocystin/polyductin [23, 27, 28, 32, 33]; the
molecular/cellular pathogenesis and cystogenesis of the disease [24, 28]; diagnostic
applications [34]; and therapeutic interventions for patients suffering from ARPKD [24,
28]. This research has encompassed the use of many laboratory animal models of
ARPKD including the Pkhd1 del 2/del 2 mice [27L the polycystic kidney {PCK) rat [33] and
the lewis polycystic kidney {LPK) rat [35]. There is little evidence to show that
metabolomics has been identified as a tool to investigate ARPKD. Therefore, the
purpose of this research is to utilise the LPK rat model to investigate the ARPKD
phenotype using a metabolomics approach.

1.3

Research Questions

1.

Is it possible to accurately and reliably detect metabolites in Lew/LPK
rat urine using GC/MS?

2.

Can this method be optimised to see a greater profile of metabolites at
lower detection limits?

3.

Are there any significant differences between the metabolic profiles of
Lewis and LPK rats?
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1.4

Definitions of Selected Terms

ADPKD

Autosomal dominant polycystic kidney disease

AEC

Animal Ethics Committee

AN OVA

Analysis of variance

ARC

Animal Resources Centre

ARPKD

Autosomal recessive polycystic kidney disease

ESRD

End stage renal disease

eV

Electron volt

GC

Gas chromatography

GC/MS

Gas chromatography mass spectrometry

IS

Internal standard

LC

Liquid chromatography

LC/MS

Liquid chromatography mass spectrometry

LEW

Lewis

LPK

Lewis polycystic kidney

m/z

Mass-to-charge ratio

M

Moles per litre

mg

Milligram

mL

Millilitre

MeOH

Methanol

MS

Mass spectrometry

MSTFA

N-methyi-N-(trimethylsilyl)trifluroacetamide

ng

Nanogram

ng.~L- 1

Nanograms per microlitre

NIST

National Institute of Standards and Technology
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1

H NMR

Proton nuclear magnetic resonance

p

Probability.

PC1

Principal component 1

PC2

Principal component 2

PCA

Principal component analysis

PCK

Polycystic kidney

PKD

Polycystic kidney disease

PKD1

Polycystic kidney disease 1 gene

PKD2

Polycystic kidney disease 2 gene

PKHD1

Polycystic kidney and hepatic disease 1 gene

u

Unit

U.~-tL- 1

Units per microlitre

1-lg

microgram

Ill

micro litre
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CHAPTER TWO
METHODS

2.1

Chemicals

D-mannitol (>99%), ribitol (>99%), methoxyamine-HCI (98%), N-methyi-N(trimethylsilyl)trifluroacetamide (MSTFA) (>98.S%), pyridine (>99%), n-alkanes C10, C12,
1
C1s, C19, C22, C2s, C32 and C36 (>98%), type Ill jack bean urease (40100 U.g- ) and
creatinine (>98%) were all purchased from Sigma Aldrich; Australia. n-hexane (>9S%)
and methanol (HPLC grade >99%) were purchased from LabScan; Australia. Helium
cylinders (UHP) were purchased from BOC Gases; Australia.

2.2

Standards

Seven concentrations (0.01, O.OS, 0.1, 0.5, 1, S and 10 ng.jlL-1) of D-mannitol
were prepared to calculate limit of detection (LOD) and precision of the GC/MS. A
stock solution of D-mannitol (6.5 mg.L-1) was prepared from which 0.1, O.S, 1, S, 10
and SO ml aliquots were taken and made up to 100 ml with milli-Q water (the stock
was used to prepare the 10 ng.jll-1 standard). The internal standard, ribitol, was added
to each at a desired final concentration of SO ng.jll-1. Multiple 100 Ill aliquots of each
of the standards were dried in an Eppendorf Concentrator Plus vacuum concentrator
and were either derivatised for GC/MS analysis or frozen at -80°C until further use. A
similar approach was taken to add ribitol to experimental samples, however the
1
desired final concentration was 1S ng.jll- . n-alkanes were used for Kovats Index
calculation. Individual solutions of the each of the alkanes were made up to 1 ml in
hexane at a concentration of O.S mg.ml-1. An alkane mixture was prepared from the
individual solutions at a concentration of 0.062S mg.ml-1 in 8 ml.
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2.3

Laboratory Animals

Lewis and LPK rat urine samples were purchased from the Animal Resources
Centre (ARC), Canning Vale, Western Australia. The animals were housed together in
cages with steam cut wheaten chaff, at ambient temperature (20-25°C}. The animals
were fed a vegetarian diet of Standard Laboratory Rat and Mouse Cubes (Specialty
Feeds, Glen Forrest; Western Australia) and had water available at all times. Phillips

eta/. [35] outlines the method by which the disease was transmitted to the laboratory
animals and also the method by which the mode of inheritance (autosomal recessive)
was characterised. Spot urine samples (50-500 IJ.L) were collected from 3 male Lewis; 2
female Lewis; and 5 male LPK rats aged approximately 11 weeks. These samples were
pooled and used for method development. For experimental work, urine was collected
from 7 male Lewis; 8 male LPK; and 6 female LPK rats aged 5 weeks. Registration as an
animal researcher was sought and approved by Murdoch University's Animal Ethics
Committee (AEC) and ethical approval for this study was sought and approved by Edith
Cowan University's AEC. Approval number: Project 2144 MARTINS; Investigating Betaamyloid clearance in vivo 06-A9.

2.4

Metabolite Extraction

Urine from Lewis rats (control) was used to optimise the extraction procedure.
Samples from 11-week old male and female rats were pooled (50 IJ.L unless otherwise
stated) and urease (1 unit per microlitre of urine unless otherwise stated) was added.
The samples were incubated at 37"C (30 minutes unless otherwise stated). The
samples were then centrifuged at 4000 rpm for 10 minutes. Following this,
-40oC methanol containing the ribitol internal standard was added to the sample. The
calculation for the concentration of ribitol in the extraction solvent was based on
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achieving a final ribitol concentration of 15 ng.11L- 1 or 15 ng 'on column'. The samples
were then agitated at 1200 rpm for 10 minutes and following this were centrifuged at
4°C and 12000 rpm for 10 minutes. Aliquots {50 11L) of the sample were dried in an
Eppendorf Concentrator Plus vacuum concentrator and frozen at -80°C until further
use.

2.5

Metabolite Derivatisation
1

Extracted metabolites were treated with 20 11L of 20 mg.ml- methoxylamineHCI in pyridine and agitated at 1200 rpm at a temperature of 30°C in an Eppendorf
Thermomixer Comfort {NSW, Australia) for 90 minutes. Following this, 40 11L of Nmethyi-N-{trimethylsilyl)trifluroacetamide {MSTFA) was added and the metabolites
were incubated at

3rc

for 30 minutes in the thermomixer. The metabolites were

agitated for the first 1-2 minutes of this incubation period to mix the MSTFA. The 60 11L
sample was then transferred to a 31 x 5 mm 0.1 ml clear GC vial insert inside an
Alltech GC vial containing 5 11L of an alkane mix in hexane.

2.6

Instrumentation

2.6.1

Quadrupole GC/MS (Murdoch University)

An Agilent 6890 series Gas Chromatograph equipped with an Agilent 5973N
mass selective detector was used. The column employed was a Varian Factor Four
fused silica capillary column VF SMS {30 m x ID

=0.25 mm x DF =0.25 11m+ 10 m EZ-

Guard). The derivatised sample {1 11L) was injected splitless into the inlet at a
temperature of 230°C. The initial column temperature was 70°C and the temperature
ramp was set to 5.63°C.min-1 to a final temperature of 330°C. The carrier gas used was
helium at a flow rate of 1 ml.min-1 {constant flow). The transfer line was set at 330°C
and the ion source was set to 230°C. Ionisation was achieved with a 70 eV electron
12

beam and the mass spectrometer was set to scan ion masses in the range of 45 - 600

m/z.
2.6.2

lon trap GC/MS (Murdoch University)

A Varian CP 3800 Gas Chromatograph (Australia) equipped with a Varian 1177
split/splitless capillary injector, Varian CP 8400 autosampler (Australia) and a Varian
Saturn 2200 GC/MS/MS ion trap mass spectrometer (Australia) was used. The column
employed was a Varian Factor Four fused silica capillary column VF 5MS {30 m x ID
0.25 mm x DF

=

=0.25 11m + 10 m EZ-Guard). The derivatised sample (1 IlL) was injected

splitless into the inlet at a temperature of 230°C. The initial column temperature was
1

70oC and the temperature ramp was set to 5.63°C.min· to a final temperature of
330°C. The carrier gas used was helium at a flow rate of 1 mL.min-1 (constant flow).
The transfer line was set at 330°C and the ion source was set to 230°C. Ionisation was
achieved by a 70 eV electron beam and the mass spectrometer was set to scan ion
masses in the range of 45- 600 m/z.

2.6.3

lon trap GC/MS (Edith Cowan University)

A Varian Star 3400 CX gas chromatography system (Australia) equipped with a
Varian Saturn 2000 GC/MS/MS ion trap mass spectrometer (Australia) was used. The
column employed was a Varian Factor Four fused silica capillary column VF 5MS {30 m
x ID

=0.25 mm x DF =0.25 11m + 10 m EZ-Guard). The derivatised sample (1 IlL) was

injected splitless into the inlet at a temperature of 230°C. The initial column
temperature was 50°C and was ramped to 70oC in the first 2 minutes of the run time.
1

Thereafter the temperature ramp was set to 5.60oC.min· for 45.35 minutes to a final
temperature of 330°C. The carrier gas was helium at a flow rate of 1 mL.min-

1

(constant pressure). The transfer line was set at 330°C and the ion source was set to
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230°C. Ionisation was achieved by a 70 eV electron beam and the mass spectrometer
was set to scan ion masses in the range of 45- 600

2. 7

m/z.

Data Analysis
GC chromatograms and mass spectra were viewed using AnalyzerPro v2.2.0. 7

{SpectraiWorks, UK). AnalyzerPro was used to identify all unique components (i.e.
peaks) of the chromatogram and also to identify target components, which were
stored in a user-generated library (Metabolomics Australia Node; Murdoch University).
Target components were added to the library according to retention time, Kovats
Index and deconvoluted mass spectrum (base peak). Analytes in the sample
chromatograms were resultantly matched to these parameters. In addition to being
compared with the user-generated library, spectra were compared with the National
Institute of Standards and Technology {NIST) Mass Spectral library to aid in the
identification of significant unknown metabolites. The identification generated by the
NIST library was given a probability score {%) which was based on base peak and
fragmentation pattern identification. AnalyzerPro was used to generate a Microsoft
Office Excel spreadsheet of the metabolites and their peak area in each of the samples.
This OlJtput was used to determine the precision and reproducibility of the results and
was also used to run univariate statistical and multivariate analyses. The peak area of
each metabolite was normalised to the internal standard, ribitol, and then to
creatinine.
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2.8

Statistical Analysis
Univariate statistkal analyses were conducted using SPSS v17.0. Where there

were two groups of data to compare, a paired samples t-test was used with a
confidence interval of 0.95 and significance level of P=0.05. Where there were more
than two groups of data to compare, a one-way analysis of variance (AN OVA) was used
with Bonferroni post hoc multiple comparisons. A confidence interval of 0.95 and
significance level of P<0.05 were adopted. Where it was appropriate to test for
correlations in the data, particularly between the sums of the peak areas of the
components in a sample to the peak area of the component used to normalise the
data, a Pearson correlation was employed. In this instance a confidence interval of
0.99 and significance level of P<0.01 were used. Multivariate principal component
analysis (PCA) was conducted using The Unscrambler® v9.8 software package (CAMO,
Norway). The data was log transformed using the equation x = log(x + 1).
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CHAPTER THREE
·RESULTS AND DISCUSSION

3.1

Extraction Optimisation

Urine, containing the highest number of polar metabolites in comparison to
other biofluids, offers a rich source of metabolic information and is commonly used for
metabolomics research [9, 10, 15, 16, 25, 36-39]. Urine was of particular interest in this
research as the focus was on kidney disease. There is currently no agreed guideline for
sample preparation and analysis of urine for metabolomics [40]. For this reason, it was
necessary to undertake an extraction optimisation study to suit the operating
conditions of the various GC/MS systems. This involved optimising urease incubation
(concentration and incubation time), the urine volume extracted, and centrifugation
procedures. The results and discussion of these parameter~ are detailed below.

3.1.1

Urease incubation

Urea is present in high concentrations in urine and has the potential to obscure
closely eluting analytes and overload the mass spectrometer [15]. This issue is
commonly resolved by adding urease [9, 15, 18, 19] which catalyses the hydrolysis of
urea (Cb(NH 2 h) to carbon dioxide and ammonia. Initially, urease was added to a
200 j..lL pooled urine sample (11-week Lewis male and female) at a concentration of
1

0.3 U.j..lL- of urine and was incubated at 3rc for 10 minutes. The sample was then
dried and derivatised with MSTFA as previously described in section 2.3. The resulting
chromatogram (Figure 1) shows an overloaded peak in the region of RT 16.7-19.8
minutes which was attributed (by retention time and mass spectral analysis) to urea.
Zhang et a/. [15] reported that 0.15 units of urease per microlitre of urine and an
incubation period of 15 minutes was adequate to degrade urea from rat urine,
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however the results here clearly showed the need for a greater concentration of
urease and an extended .incubation period for the Lewis/LPK rat urine. It can also be
8

seen that the intensity of some of the other analytes was 1.2 x 10

,

suggesting

overloading, which was attributed to the volume of urine used (200 j...tl). Therefore, the
experiment was repeated with three modifications: 1. the units of urease added per
microlitre of urine was increased to 1; 2. the incubation period was increased to 30
minutes; and 3. the volume of urine treated with urease was decreased to 50 j...tl. The
resulting chromatogram (Figure 2) showed that the urea peak, located at RT 16.7
minutes, did not exhibit excessive overloading. By comparing Figures 1 and 2 it can be
seen that there are a greater number of peaks in Figure 1. This is due to the greater
volume of urine used to extract metabolites (i.e. 200 j...tl compared to 50 j...tl). This
comparison is summarised in Table 1, along with the results of experiments using two
other extraction volumes (25 j...tl and 10 Ill).
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Figure 1. GC/MS chromatogram of a 200 Ill urine extract. 0.3 units of urease were
added per microlitre of urine which was then incubated for 10 minutes.
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Figure 2. GC/MS chromatogram of a 50 I-ll urine extract. 1 unit of urease was added
per microlitre of urine and was incubated for 30 minutes.

3.1.2

Urine volume

Initial experiments involving catalysed urea hydrolysis saw the need to
investigate the extraction volume of urine. Table 1
(mean

show~

the number of components

± SD) and target components (mean ± SD) detected in four different extraction

volumes of pooled 11-week old male and female Lewis rat urine. It can be seen here
that there is a significant difference (P<0.05) between each of the volumes tested and
there is a significant correlation (P<0.01) between the number of components found
and the urine volume, demonstrating good linearity of the assay method. There is no
significant difference between the number of target components found for the
volumes 25 I-ll, 50 I-ll and 200 I-lL At an earlier stage, it was concluded that 200 I-ll of
urine contributed an overload of material on the GC column (Figure 1), however it also
yielded the greatest total number of components (Table 1). Extracted urine volumes of
10, 25 and 50 1-tl showed significantly less components than 200 I-ll (P<0.01), however
there was much less evidence of overloading with these smaller extraction volumes. A
50 I-ll extract is shown in Figure 2 with a maximum ion intensity of 3 x 10

7

•

Although
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there was no significant difference between the number of target components
detected with the 2S and 50 j.tl volumes, it was concluded that SO j.tl was the optimum
volume to proceed with due to the presence of a significantly higher total number of
components detected (Table 1).

Table 1. Number of components (mean ± SD) and target components (mean ± SD)
detected in 10, 2S, SO and 200 j.tl extraction volumes of urine.
Urine Volume Samples
Number of Target
Number of Components

{j.tl)

(n)

10

3

71 ± 4t#¥

so± s

2S

3

164 ± 2S*#¥

93 ± 6*

so

3

230 ± 9*t¥

108 ± 3*

200

s

S80 ± 26*t#

100 ± 8*

Components

*significantly different from 10 j.tl (P<O.OS), t significantly different from 2S j.tl (P<O.OS),
#significantly different from SO j.tl (P<O.OS), ¥significantly different from 200 j.tl
(P<O.OS).

3.1.3

Centrifugation

Some debate has centred on the effect of centrifuging urine prior to
metabolomic analysis, specifically, the potential loss of metabolites in the sediment of
the urine during centrifugation [9]. Urine samples (in triplicate) with and without an
initial centrifugation step (see section 2.2) were prepared for extraction. The number
of components (mean

± SD) and target components (mean ± SD) that were detected

are shown in Table 2. Centrifugation resulted in 473 ± 7 components and 44 ± 1 target
components being detected and the non-centrifuged samples resulted in 436 ± 33
components and 43 ± 4 components being detected. There was no significant
difference between the number of components and target components found
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between the centrifuged and non-centrifuged groups; which show that initial
centrifugation does not affect the number of metabolites detectable in Lewis and LPK
rat urine by GC/MS. A

et a/. [9] found that metabolites such as myo-inositol, urate,

hippurate, glycerate, p-hydroxyphenylacetate and a few other unidentified compounds
were found in greater concentrations in a non-centrifuged group of rat urine.
However, A

et a/. [9] also found that centrifugation improved the response of

metabolites such as creatinine, phosphorate and allantoin and predicted that this was
due to improved trimethylsilylation for the lower concentrations of analytes in the
centrifuged supernatants. Since one of the main aims of this study was to develop a
method for non-targeted urinary metabolic profiling, it was decided that the
centrifuged method should be adopted for effective trimethylsilylation, particularly
because creatinine was to be used as a normalisation technique.

Table 2. Number of components (Mean ± SD) and target compounds (Mean ± SD)
detected with and without the initial centrifugation step in the extraction method (n =

3).
Treatment

Number of Components

Number of Target
Components

Centrifuged
Non-centrifuged

473 ± 7

44 ± 1

436 ± 33

43 ±4
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3.2

Instrumentation

3.2.1

limit of detection

Limit of detection is determined by a signal (detector response) that is three
times the baseline noise. Low detection limits are important for the detection of low
abundance metabolites in non-targeted metabolomics [11]. Trimethylsilylated Dmannitol was used to determine the LOD of three different GC/MS systems at two
sites (Table 3). Seven different concentrations (0.01, 0.05, 0.1, 0.5, 1, 5 and 10 ng.llL-1)
of D-mannitol were analysed with splitless injections (1 IlL) on each of the instruments
to obtain the limit of detection. The most sensitive instrument was the ion trap GC/MS
at Murdoch University (with an LOD of 0.10 ng on column) followed by the quadrupole
GC/MS at Murdoch University (with an LOD of 0.14 ng on column). These results were
expected as ion trap mass spectrometers trap all ions and destabilise their trajectories
in order that they reach the detector in a uniform stream. Linear quadrupole mass
spectrometers, however, stabilise the ion trajectory for a given m/z species, but this
can result in the loss of sensitivity for the destabilised ions. An LOD could not be
obtained for the ion trap GC/MS at ECU due to the apparent absence of D-mannitol. It
was proposed that D-mannitol was co-eluting with n-nonadecane which resulted from
the operation of the instrument in constant pressure mode, the only mode available
due to the age of the instrument. To rectify this problem, the pressure was reduced
slightly (from 15 to 14 psi) and the temperature ramp was increased in the second
segment of the run (from 1.0 to 1.1 oc.min- 1). This saw a small peak eluting after nnonadecane even though the concentration of D-mannitol was 100 ng on column and
should have been an intense peak in comparison to the alkane. This resulted in the
exclusion of the GC/MS at ECU due to the inferior sensitivity it exhibited for a
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compound which is typical of metabolite properties. This finding was supported in
section 3.2.2.

Table 3. Comparison of the limit of detection (ng on column) of a quadrupole GC/MS
system and two ion trap GC/MS/MS systems at two different sites.

Institution

Limit of Detection

Quadrupole GC/MS

Murdoch

0.14

lon Trap GC/MS

Murdoch

0.10

lon Trap GC/MS

ECU

ND

Instrument

3.2.2

Detectable components

As the limit of detection was not particularly different between the quadrupole
GC/MS and the ion trap GC/MS at Murdoch University, urine samples were prepared
using the optimised extraction method and run on both instruments as well as the ion
trap GC/MS at ECU. Surprisingly, the quadrupole GC/MS returned a significantly higher
(P<O.OS) number of components than the ion trap GC/MS at Murdoch University in
both the centrifuged and non-centrifuged groups (Table 4). The ion trap GC/MS at ECU
showed significantly less (P<O.OS) components than both of the GC/MS systems at
Murdoch, however, these results were expected due to the inferior limit of detection.
The number of target components was not reported here as the AnalyzerPro usergenerated library was created using the quadrupole GC/MS at Murdoch University
with D-mannitol retention time lock based retention times. For this reason, library
matched components would not be returned for either of the ion trap instruments.
This could not be corrected with retention time locking as Varian instruments do not
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have this functionality. As a result of these findings, it was decided to proceed with
urine analysis using the linear quadrupole GC/MS.

Table 4. Comparison of the number of components (mean± SD) detected in pooled 11
week old male and female Lewis rats by the quadrupole GC/MS system and two ion
trap GC/MS/MS systems (n 3).

=

Instrument

Number of Components
Non-centrifuged

Centrifuged

436±33t#

Quadrupole GC/MS (Murdoch)
lon Trap GC/MS (Murdoch)

152 ± 13*#

160 ± 7*#

lon Trap GC/MS (ECU)
*Significantly different from Quadrupole GC/MS (Murdoch), tsignificantly different
from lon Trap GC/MS/MS (Murdoch), #significantly different from lon Trap GC/MS/MS
ECU.

3.2.3

Precision and reproducibility

A standard curve generated for quantitative analysis is also a useful measure of
precision for both sample preparation and instrumentation steps. Figure 3 shows the
peak area

of five

different concentrations

(0.1, 0.5,

1, 5,

10 ng.j..!L-

1

)

of

trimethylsilylated D-mannitol splitless injections (1 j..!L) on the quadrupole GC/MS at
2

Murdoch. The R value of 0.9994 indicates a precise and reproducible method and
system for the concentrations between 0.1 to 10 ng of trimethylsilylated D-mannitol
on column. D-mannitol was used to obtain LOD, precision and reproducibility data as
the majority of the high throughput metabolomics work in this laboratory has been
carried out on fungi, for which D-mannitol was the most abundant compound
detected. Additionally, D-mannitol has been utilised by Metabolomics Australia to lock
retention times of instruments across Australia. D-mannitol is cheap, and elutes at
23

approximately half of the total GC/MS analysis time, making it useful for these
experiments and also for retention time locking. Internal standards are also used as a
measure of method reproducibility [6, 15]. Figure 4 shows the peak area of 50 ng.J..LL-

1

of the internal standard trimethylsilylated ribitol in each of the injected D-mannitol
standards. The relative standard deviation (RSD) of the ribitol peak area was 2.68%
which indicated that the assay (sample preparation and instrumental analysis) was
highly reproducible. Ribitol was used as an internal standard because it is not present
in fungi (nor is it present in mammals) and elutes before the 30 minute {sugar
overload' in fungal samples, and is therefore readily resolved. There are many other
2

internal standards that have proven to be stable and reliable such as [ H3]myristic acid
[15], succinic d4 acid, malonic d 2 acid, glycine d5 and glucose
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C6 [6]. However, due to

the ready availability, the low cost, and the recent success using D-mannitol and ribitol,
these procedures were continued.
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3.2.4

=

Injection mode

A split injection is commonly used to achieve baseline separation when the
concentration of a sample is known to be high or i·s unknown. It is a preventative
measure to minimise overloading. This is especially the case when using capillary
columns as tens of micrograms of analyte can cause overloading. Although splitless
injections are widely used in non-targeted urinary metabolic profiling [9, 15, 17, 19], a
split injection was tested in an attempt to improve signal-to-noise ratio and resolution,
and to minimise overloading. Whilst the chromatography was improved, the number
of components detectable was reduced significantly (P<O.OS). Table 5 shows the
number of components (mean ± SD) and target components detected using splitless
and split (20:1) injections. The splitless method resulted in the detection of 473 ± 7
components and 44 ± 1 target component library matches. The 20:1 split method,
however, resulted in the detection of only 179

± 7 components and 18 ± 0 target

component library matches. Due to these findings, subsequent injections were
performed in splitless mode.
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Table 5. Number of components (mean ± SD) and target components (mean ± SD)
detected using splitless and split (20:1) GC methods (n =3).

Number of Components

Number of Target Components

Splitless

473 ± 7

44± 1

Split (20:1)

179 ± 7*

18 ± O*

Treatment

*significantly different from splitless.

3.3

Data Analysis
From the 584 ± 44 components detected in the male Lewis rat urine (n

=7) only

92 ± 5 were library matched (target components) (Table 6). For female LPK rat urine (n

= 4)

554 ± 31 components were detected of which 96 ± 5 were library matched.

Analysis of male LPK rat urine resulted in the detection of 587 ± 47 components of
which 94 ± 5 were library matched. There was no significant difference between the
number of components and target components found in the two strains and sexes.

Table 6. Number of components (mean ± SD) and target components found in Lewis
male and LPK male and female rat urine.
Number of Target Components
Number of Components
Replicates
Strain ··Sex

Lewis

Male

7

585 ± 44

92 ± 5

LPK

Female

4

554 ± 31

96 ± 5

LPK

Male

6

587 ± 47

94± 5
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3.3.1

Normalisation

As mentioned previously, internal standards are a measure of methodology
reproducibility and can highlight if the signal-to-noise ratio changes between analyses.
Ribitol was added to each of the urine samples at a desired final concentration of
15 ng.~L- 1 or 15 ng on column. By doing so, each of the peaks in a particular sample
were normalised to the internal standard to account for any variability in both the
sample preparation and the instrument. Trimethylsilylated ribitol is a target
component in the AnalyzerPro user-generated library. In addition to this, the mass
spectrum of the compound was obtained, as was the deconvoluted mass spectrum, to
ensure the library match was accurate and to further ensure data was being
normalised to the correct component. There was a significant correlation {P<0.01)
between the sum of the peak area of all components in the sample to the respective
ribitol peak area. Based on this result it was assumed that if ribitol was affected by
sample preparation and instrument variability, all peaks were subsequently affected
and normalisation to account for this was therefore warranted. Figure 5 shows the
peak area of ribitol in each of the urine samples, showing a relative standard deviation
{RSD) of 14.02%. A desirable RSD is <10%, however, due to the limited volume of
sample obtained from the rats, this experiment could not be repeated.
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Figure 5. Peak area of trimethylsilylated ribitol in each of the rat urine samples (%RSD

= 14.02). Samples are labelled strain (LEW/LPK), sex (M/F) and from A-H for individual
identification.

Biofluids such as plasma, serum and cerebrospinal fluid are physiologically
controlled,

however, urine can

be particularly varied, mainly due to water

consumption, but also as a result of other factors [39]. Although food and water were
available to the animals at all times, it was expected that hydration state would affect
the concentration of metabolites in the urine and potentially cause significant
variability in the metabolic profiles, masking any differences that may have been seen
as a result of disease state. To correct for this, creatinine was identified as a potential
normalisation strategy. This is common practice in clinical chemistry and metabolomics
as creatinine is an indicator of the concentration of urine, assuming a constant
secretion of creatinine into urine [36, 39]. The focus of this study was ARPKD.
Therefore, there was concern that creatinine levels would be significantly lower in the
LPK animals than in the Lewis. The result of a one-way ANOVA found that there was no
significant difference in creatinine attributed to sex and/or strain. This finding was
supported by Phillips eta/. [35] who found that serum creatinine was not significantly
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increased in the LPK rat until age 12-weeks. In order to positively identify creatinine in
the samples, a standard was derivatised and run on the quadrupole GC/MS at
Murdoch University. The retention time of creatinine was found to be 23.4 minutes
(Figure 6) and the base peak

m/z 115 (Figures 7 and 8). In order to add creatinine to

the existing AnalyzerPro library, a deconvoluted mass spectrum was obtained (Figure
8) which excludes interferences such as

m/z 73 which is attributed to trimethylsilyl

groups. The deconvoluted mass spectrum aids in the identification of the correct base
peak. After the addition of creatinine to the library, the data was re-processed to
include the identification of creatinine. To ensure that it was correct to assume
creatinine levels would increase and decrease with changing metabolite concentration,
the sum of all peak areas in the sample were correlated to the respective creatinine
peak area. This was found to be significant (P<O.Ol) after ribitol normalisation.
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Figure 6. GC Chromatogram of trimethylsilyl creatinine (RT 23.4 minutes).
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3.3.2

Principal component analysis

Principal component analysis has been employed in metabolomics studies using GC [8,
9, 15, 17), LC [2, 41-44], MS [11, 22, 39] and 1H NMR [16, 36, 38, 45, 46]. It is a method
of data transformation that assigns the data a coordinate system whereby in any
projection of the data (20 or 30), the greatest variance {%) lies on the first coordinate
(principal component 1). Principal component 2 shows the next greatest variance and
so on. Figure 9a shows the principal component analysis of male and female 5-week
old Lewis and LPK rats. This 2-0 projection of data was generated using the logtransformed raw peak area of target components. At this point, the target components
had not been normalised to ribitol or creatinine. 18% of the variance between the
samples was attributed to PC1 and 14% was attributed to PC2. The remaining principal
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components 3-15 inclusive (not shown) explain $9% of variance. With only 32% of
variance explained in PCl and PC2 and clear overlapping of the sample groups, this
model provides little information regarding variability in metabolites as a function of
disease state.
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Figure 9a. Principal component analysis of male and female 5-week old Lewis and LPK
rat urine samples. This output was generated using log-transformed peak area data.

Figure 9b shows the principal component analysis of male and female 5-week
old Lewis and LPK rats. This projection of data was generated using the logtransformed peak area of target components normalised to the internal standard
ribitol. PC1 explained 28% of the variance between samples and PC2 explained 17% of
the variance. PC3-15 (not shown) explained

~ 14%

of variance. With an overall

explained variance of 45% in PC1 and PC2, it was concluded that 13% (i.e. the
difference in explained variance between Figures 9a and 9b) of variance between
samples was attributed to the concentration of metabolites in the individual samples
(i.e. overloading) and not to sample preparation and instrumental analysis. Results
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reported previously in this section (3.2.3) indicate that the sample preparation and
instrumental analysis were highly reproducible with a relative standard deviation of
2.68% for the internal standard ribitol. Section 3.3.1, however, reports the relative
standard deviation of 14.02% for the internal standard, ribitol. This result (Figure 9b)
was therefore expected as the signal-to-noise ratio changed between biological
replicates while the signal-to-noise ratio between technical replicates stayed relatively
stable. Figure 9b once again shows overlapping of sample groups showing little
discrimination between diseased and non-diseased animals.
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Figure 9b. Principal component analysis of male and female 5-week old Lewis and LPK
rat urine samples. This output was generated using log transformed peak area data
normalised to the internal standard ribitol.
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Figure 9c shows the principal component analysis of male and female 5-week
old Lewis and LPK rats·. This projection of data was generated using the logtransformed peak area of target components normalised to ribitol and then creatinine.
40% of the variance between samples is explained by PC1 and 16% by PC2. PC3-15 (not
shown) each explained ::;; 13%. Therefore, 56% of the total variance was explained by
the model (PC1 and PC2), of which, 11% was attributed to variation in analyte
concentration due to the hydration state of the animal. Figures 9a-c shows the
importance of data transformation and normalisation. These processes minimise the
impact of variability of high intensity peaks [11] and further illustrate the need for high
inter-sample reproducibility. Even more so than Figures 9a and 9b, there was a clear
overlap in sample groups. Having accounted for signal-to-noise variability and
hydration state, it was expected that this model represented variability attributed to
individual target components in the samples. Although there is an overlap in sample
groups, it was seen here that the 5 male animals on the right are the key influence
attributing to the variance explained by PC1 (40%). Given that 80% of the animals
influencing PC1 were Lewis males, it was noticed that male diseased and non-diseased
animals began to show discrimination (Figure 10) after the various normalisation
techniques.
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Figure 9c. Principal component analysis of male and female 5-week old Lewis and LPK
rat urine samples . This output was generated using log transformed peak area data
normalised to ribitol then creatinine .

These results (Figures 9a-10) show that PCA is a powerful tool for visualising
metabolomics data . These models (Figures 9a-c) are representative of approximately
100 metabolites for 17 individual animals. PCA is commonly used to identify specific
metabolites which are attributed to variations between disease states [8, 36, 44, 46],
however, it can also be used as a method for data mining to identify interferences due
to assay method [15]. In this case, it has been used for both. The X-loadings plot for
the PCA in Figure 10 (Figure 11) revealed that the metabolites attributing to the
variance between sample groups were, but were not limited to, D-mannitol, aketoglutarate, uric acid, allantoin and phosphoric acid. The presence of D-mannitol is
an indication that the chromatographic separations were not sound for the samples
that attributed to the variance. In particular, the presence of D-mannitol is an
indication that there was overloading in the samples as higher eukaryotes do not
synthesise or catabolise D-mannitol [47]. This finding is indicative of a shift in retention
time due to overloading and resultant misidentification of peaks. It was postulated
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that the presence of 0-mannitol was the result of the presence of a closely eluting
sugar with a similar fragmentation pattern . For this reason, 0-mannitol was not
excluded from the data analysis as it may represent an important sugar which should
be investigated further in the future . The presence of a-ketoglutarate, uric acid and
allantoin, however, are indicative that the groups are likely to be separated due to
disease state. a-ketoglutarate has been linked to hypertension by Akira eta/. [36], and
hypertension has been identified as a clinical symptom of ARPKO in the LPK rat by
Phillips eta/. [35] . Further, it is postulated that uric acid and allantoin may be linked to
renal and/or liver dysgenesis. The reason for the presence of phosphoric acid in the Xloadings plot remains unknown. It has been postulated that it is an artefact of sample
preparation . Whilst these findings show a solid foundation for investigating ARPKO
using metabolomics, food and water intake and urine collection (i.e . spot urine) cannot
be ruled out as factors influencing variance. Walsh et a/. [40] have identified urinary
metabolomics as an effective method of determining and

assessing dietary intake

which suggests that food and water should be withheld from the animals to eliminate
this as a factor attributing to variance. Similarly, Walsh eta/. have identified the need
to investigate the difference between 24-hour samples and spot samples. Akira eta/.
[36] were able to explain 76% of variance between young spontaneously hypertensive
rats and healthy controls using a PCA model after creatinine normalisation. Similarly,
Vallejo et a/. were able to explain 94% of variance between atherosclerosis patients
and healthy controls using a PCA model. The total explained variance of the PCA in
Figure 10 is 68%. This comparatively low explained variance may be attributed to the
limitations of the study, in particular, food and water intake, and limited sample size.
In this analysis (figure 10) principal components 3-15 (not shown) explain

~

15% of

variance. This suggests that there is further interpretation needed for this data set with
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respect to principal components beyond PCl and PC2 . In order to do so, all of the
limitations of the study need to be identified to make accurate and reliable
interpretations regarding the influence of individual metabolites.
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Figure 10. Principal component analysis of male 5-week old Lewis and LPK rat urine
samples. This output was generated using log transformed peak area data normalised
to ribitol then creatinine.
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This output was generated using log transformed peak area data normalised to ribitol
then creatinine and shows the key metabolites which influence the model described in
Figure 10.
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CHAPTER FOUR
CONCLUSION

4.1

Conclusion

There are some interesting findings in the present research, the overall
outcome of this work being the identification of the need for a well-controlled
experiment with a greater sample size. With the development of an optimised method
for non-targeted urinary metabolic profiling of the LPK rat, it is hoped that a
metabolomics approach may lead to the identification of biomarkers for ARPKD in the
future. Once the phenotype of the LPK rat model of ARPKD has been thoroughly
investigated, it is hoped that the findings will contribute to research in human ARPKD.
The findings of this study, particularly the development of a GC/MS method to analyse
Lewis and LPK rat urine, demonstrate the potential of (lletabolomics to investigate
ARPKD. The work in this project has provided preliminary data demonstrating the
ability to differentiate urine samples on the basis of sex and disease state. Future
detailed temporal studies are hoped to elucidate key metabolites to identify the onset
of kidney dysgenesis and aid in determining the function of the ARPKD protein
fibrocy~tin/polyductin.
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4.2

Recommendations

The user generated library at the Metabolomics Australia Node; Murdoch
University, primarily consists of polar plant metabolites and for further work;
mammalian metabolites and non-polar metabolites, including lipids, need to be added
to the library. This can be carried out by complementary analytical techniques such as
1

H NMR to elucidate the structures of the unknown analytes in the samples. These

results would then be validated with pure standards. Controlled sample collection,
including food and water prior to sampling, and further optimisation of sample size will
improve reproducibility of data in the future. Furthermore, the role of creatinine as an
appropriate urine normalisation technique as a function of kidney dysgenesis needs to
be investigated. This can be undertaken as a temporal animal based study with
adequate biological replicates.
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